Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00496509
First received: July 3, 2007
Last updated: April 24, 2015
Last verified: April 2015
  Purpose

A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases.


Condition Intervention Phase
Colorectal Cancer
Drug: ZD6474 (Zactima) 100mg
Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)
Procedure: Biomarker Draws
Drug: ZD6474 (Zactima) 300mg
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases. [ Time Frame: Up to 57 days. ]

Secondary Outcome Measures:
  • Assessment of appropriate Pharmacokinetic parameters [ Time Frame: Predetermined timepoints after dose administration ]
    The exposure to ZD6474 in patients with advanced colorectal cancer and liver metastases by assessment of: maximum plasma concentration after single and at steady state (C max and Css, max); time to reach C max and Css, max (tmax); minimum plasma concentration before and at steady state (Cmin and Css, min); area under plasma concentration-time curve from zero to 24 h and at steady state (AUC(0-24) and AUCss); total body clearance of drug from plasma after an oral dose (CL/F): accumulation ratio (Rac) and fraction of ZD6474 unbound (fu).

  • Determine the population PK of ZD6474 and assess the relationship between both free and total plasma PK and measures of Pharmacological activity [ Time Frame: Predetermined timepoints after dose administration ]
    Determination of the population PK of ZD6474 and the assessment of the relationship between both free and total plasma PK and measures of pharmacological activity by assessment of individual predicted plasma concentrations, individual predicted CL/F, AUCss, Css, max, and AUC to the point up to the scan.

  • Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST. [ Time Frame: Every 8 weeks during the study ]

Enrollment: 24
Study Start Date: August 2006
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ZD6474 (vandetanib) 100mg Drug: ZD6474 (Zactima) 100mg Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR) Procedure: Biomarker Draws
Experimental: ZD6474 (vandetanib) 300mg Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR) Procedure: Biomarker Draws Drug: ZD6474 (Zactima) 300mg

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed metastatic colorectal adenocarcinoma (stage IV) with at least 1 measurable hepatic lesion of 20 mm or more on MRI and for whom no standard therapy is available.
  • WHO Performance status 0 - 2.
  • Life expectancy of at least 12 weeks

Exclusion Criteria:

  • Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry and stable without steroid treatment for 10 days or greater.
  • Last dose of prior chemotherapy must be discontinued at least 4 weeks before the start of study treatment.
  • Last dose of radiotherapy received within 4 weeks before the start of study treatment excluding palliative radiotherapy.
  • Prior treatment with VEGFR TKIs
  • Serum bilirubin . 1.5 x the upper limit of reference range.
  • Serum creatinine >1.5 x ULRR or Creatinine clearance (as determined by the Cockcroft - Gault method) less than or equal to 50 mL/min.
  • ALT or AST >5 x ULRR
  • ALP >5 x ULRR
  • Evidence of severe or uncontrolled systemic disease or any concurrent conditions which in the investigators opinion make it undesirable for the patient to participate in the study or would jeopardize compliance with the protocol.
  • Any unresolved toxicity greater than CTCAE Grade 2 for previous anti-cancer therapy.
  • Significant cardiovascular event within 3 months before entry, or presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia.
  • History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled by medication is not excluded.
  • Congenital long QT syndrome or 1st degree relative with sudden unexplained death under of 40 years of age.
  • Presence of Left Bundle Branch Block.
  • QTc with Bazett's correction unmeasurable or greater than or equal to 480 msec or greater of screening ECG.
  • Potassium <4.0 mmol/L despite supplementation, serum calcium (ionized or adjusted for albumin), or magnesium out of normal range despite supplementation.
  • Women who are pregnant or breast feeding.
  • Any concomitant medications that may cause QTc prolongation or induce or induce Torsades de Pointes or induce CTP3A4 function.
  • Hypotension not controlled by medical therapy.
  • Participation in a clinical study of any investigational pharmaceutical agent within 30 days prior to commencing study treatment.
  • Major surgery within 4 weeks or incompletely healed surgical incision.
  • Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or Squamous cell carcinoma of the skin.
  • Any contraindications to MRI scans.
  • Involvement in the planning or conduct of the study.
  • Previous enrollment or randomization of treatment in the present study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00496509

Locations
Germany
Research Site
Freiberg, Germany
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Klaus Mross, MD Albert-Ludwigs-Universitat
  More Information

Publications:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00496509     History of Changes
Other Study ID Numbers: D4200C00050
Study First Received: July 3, 2007
Last Updated: April 24, 2015
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:
ZD6474
Colorectal Cancer
Liver Metastases
Biomarkers

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases

ClinicalTrials.gov processed this record on July 05, 2015